Abstract
Biological response modifiers (BRMs) are those agents or approaches that influence the relationship between the tumor and host by modifying the hosts response to tumor cells, with resultant therapeutic activity (9). A series of studies with recombinant cytokines designed to better understand their immunomodulatory and therapeutic properties have been undertaken. The present report discusses recombinant murine interferon-gamma (rM IFN-g), recombinant human tumor necrosis factor (rH TNF), rH interleukin-2 (rH IL-2), and rM colony stimulating factor-gm (rM CSF-gm). We discuss the development of Optimal Therapeutic Protocols (OTP) for preclinical studies and initial clinical trials that have been initiated to test the resultant clinical hypotheses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
P. L. Black, H. Phillips, H. Tribble, R. Pennington, M. Schneider, and J. E. Talmadge, Immune responses in tumor-bearing organs and therapeutic activity of rM IFN-G, Fed. Proc. 46: 1499 (1987).
M. A. Cheever and P. D. Greenberg, In vivo administration of interleukin-2, Contemp. Top. Mol. Immunol. 10: 263–282 (1985).
M. A. Cheever, J. A. Thompson, D. J. Peace, and P. D. Greenberg, Potential uses of interleukin 2 in cancer therapy, Immunobiology. 172: 365–382 (1986).
B. S. Edwards, J. A. Merritt, R. C. Fuhlbrigge, and E. C. Borden, Low doses of interferon alpha result in more effective clinical natural killer cell activation, J. Clin. Invest. 75: 1908 (1985).
M. S. Ernstoff, S. Reich, Y. Nishoda, and J. M. Kirkwood, Immunological assessment of melanoma patients treated with recombinant interferon gamma (rIFN-gamma, Biogen, Inc., Cambridge, MA) in a phase I/II trial, Proc. M. Assoc. Cancer Res. 26: 280 (1985).
D. Hartmann, J. S. Adams, A. K. Meeker, M. A. Schneider, B. F. Lenz, and J. E. Talmadge, Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose in tumor-bearing mice. Cancer Res. 46: 1331–1338 (1986).
E. S. Kleinerman, R. Kurzrock, D. Wyatt, J. R. Quesada, J. U. Gutterman, and I. J. Fidler, Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res. 46: 5401–5405 (1986).
A. E. Maluish, W. J. Urba, K. Gordon, W. R. Overton, D. Coggin, E. R. Crisp, R. Williams, and S. A. Sherwin, Determination of an optimum biological response modifying (BRM) dose of interferon gamma in melanoma patients, Proc. Am. Soc. Clin. Oncol. in press (1987).
E. Mihich and A. Fefer, Biological response modifiers subcommittee report, in: “National Cancer Institute Monograph” 63:1–278 (1983).
S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, and J. M. Skibber, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Eng. J. Med. 313: 1485–1492 (1985).
S. A. Rosenberg, P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1322 (1986).
J. E. Talmadge and R. B. Herberman. The preclinical screening laboratory: Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat. Rep. 70: 171–182 (1986).
J. E. Talmadge, H. Phillips, J. Schindler, H. Tribble, and R. Pennington, A systematic preclinical study on the therapeutic properties of rH IL-2 for the treatment of metastatic disease. Cancer Res, in press (1987).
J. E. Talmadge, H. R. Tribble, R. W. Pennington, H. Phillips, and R. H. Wiltrout, Immunomodulatory and immunotherapeutic properties of recombinant gamma interferon and recombinant tumor necrosis factor in mice. Cancer Res, in press (1987).
W. H. West, K. W. Tauer, J. R. Yarnelli, G. L. Marshall, D. W. Orr, G. B. Thurman, and R. K. Oldham, Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, Biol. Ther. Cancer A 1986 Update.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Talmadge, J.E., Black, P.L. (1987). Comparison of Therapeutic Potential of Cytokines. In: Cerutti, P.A., Nygaard, O.F., Simic, M.G. (eds) Anticarcinogenesis and Radiation Protection. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6462-1_70
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6462-1_70
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-6464-5
Online ISBN: 978-1-4615-6462-1
eBook Packages: Springer Book Archive